YARW Yarrow Bioscience Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: YARW

Price (delayed)

$27.88

Market cap

$74.43M

P/E Ratio

N/A

Dividend/share

$20.12

EPS

-$21.51

Enterprise value

$51.51M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 35

VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE’s unique and proprietary BET inhibitors, which comprise ...

Highlights
YARW's debt has dropped by 100% year-on-year
YARW's EPS has soared by 52% YoY and by 13% QoQ
Yarrow Bioscience's quick ratio has surged by 119% YoY but it has decreased by 26% QoQ
YARW's equity is down by 43% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.yarrowbioscience.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of YARW

YARW stock price

How has the Yarrow Bioscience stock price performed over time
Intraday
-2.79%
1 week
7.48%
1 month
-23.46%
1 year
66.75%
YTD
-3.9%
QTD
-14.32%

Financial performance

How have Yarrow Bioscience's revenue and profit performed over time
Revenue
$482,000
Gross profit
$482,000
Operating income
-$19.93M
Net income
-$18.71M
Gross margin
100%
Net margin
-3,881.5%
YARW's operating margin has surged by 54% year-on-year and by 23% since the previous quarter
Yarrow Bioscience's operating income has soared by 53% YoY and by 18% from the previous quarter
YARW's net margin has surged by 52% year-on-year and by 18% since the previous quarter
The net income has soared by 51% YoY and by 13% from the previous quarter

Price vs fundamentals

How does YARW's price correlate with its fundamentals

Growth

What is Yarrow Bioscience's growth rate over time

Valuation

What is Yarrow Bioscience stock price valuation
P/E
N/A
P/B
0.84
P/S
49.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
106.86
YARW's EPS has soared by 52% YoY and by 13% QoQ
YARW's equity is down by 43% year-on-year and by 10% since the previous quarter
YARW's P/B is 24% above its 5-year quarterly average of 0.7 and 24% above its last 4 quarters average of 0.7
YARW's P/S is 40% below its 5-year quarterly average of 85.2 but 10% above its last 4 quarters average of 46.3
The revenue is up by 6% since the previous quarter

Efficiency

How efficient is Yarrow Bioscience business performance
YARW's return on invested capital has dropped by 86% since the previous quarter
YARW's ROS has soared by 52% YoY and by 18% QoQ
The ROE rose by 10% YoY
The ROA has contracted by 3% from the previous quarter and by 2.4% YoY

Dividends

What is YARW's dividend history
DPS
$20.12
Dividend yield
72.17%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Yarrow Bioscience financials performed over time
Yarrow Bioscience's quick ratio has surged by 119% YoY but it has decreased by 26% QoQ
The current ratio has surged by 101% year-on-year but it has declined by 27% since the previous quarter
YARW's debt is 100% smaller than its equity
YARW's debt has dropped by 100% year-on-year
YARW's equity is down by 43% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.